10-K: Beta Bionics Reports Strong Revenue Growth in 2024, Driven by iLet Bionic Pancreas Adoption

Beta Bionics' 10-K filing reveals a significant increase in revenue and installed base for its iLet Bionic Pancreas in 2024, alongside ongoing research and development efforts.

Summary

• Beta Bionics, a commercial-stage medical device company, reported its 10-K filing for the fiscal year ended December 31, 2024.
• The company focuses on developing and commercializing innovative solutions for people with insulin-requiring diabetes.
• The iLet Bionic Pancreas, cleared by the FDA in May 2023, autonomously determines and delivers insulin doses without requiring carbohydrate counting.
• The installed base of iLets grew nearly 5x, from 2,304 as of December 31, 2023, to 15,298 as of December 31, 2024.
• Approximately 69% of iLet users through December 31, 2024, were previously using multiple daily injections (MDI), while the remainder used insulin pumps or hybrid closed-loop systems.
• Revenue for the year ended December 31, 2024, was $65.1 million, a 5x increase from $12.0 million in 2023.
• Net losses were $54.8 million for 2024 and $44.1 million for 2023.
• The company is developing a patch pump and a bihormonal iLet, and plans to expand the iLet's use to treat people with insulin-dependent T2D.
• Beta Bionics is pursuing a multi-channel DME and PBP coverage and reimbursement strategy to maximize access to the iLet.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and increasing adoption of the iLet. However, ongoing net losses and the need for future capital raises temper the overall sentiment.

Positives

• The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose.
• The iLet system offers a significantly improved user experience by administering insulin without the need to count carbohydrate intake.
• The initial setup of the iLet only requires the input of the user's body weight.
• The company has a robust compendium of clinical and real-world data from more than 3,000 patients.
• The company has an extensive intellectual property portfolio with 61 issued U.S. patents and numerous foreign patents and applications.
• The company has a highly efficient business model with a 55% gross margin for the year ended December 31, 2024.
• The company has an experienced management team with extensive experience in the diabetes and medical technology industry.

Negatives

• The company has incurred significant operating losses since inception and cannot assure profitability.
• The company currently relies on sales of its iLet and related single-use products to generate all of its revenue.
• The company faces competition from numerous competitors, most of whom have far greater resources.
• The company currently has a limited marketing and sales organization and has limited experience as a commercial-stage company marketing devices.
• The company is subject to a post-market surveillance order issued by the FDA for its iLet.

Risks

• The failure of the iLet and related products to achieve and maintain market acceptance could result in sales below expectations.
• The market opportunities for the iLet for the treatment of diabetes may be smaller than anticipated.
• The company may need to raise additional funds in the future, and these funds may not be available on acceptable terms, if at all.
• The regulatory authorization process of the FDA, or any comparable foreign regulatory authorities, is lengthy, time-consuming and inherently unpredictable.
• Use of the company's commercial or development-stage products may cause adverse events or undesirable side effects or present other safety concerns.
• The company obtains some of the components and subassemblies included in the iLet from single source suppliers.
• If the company is unable to obtain or protect intellectual property rights related to the iLet, it may not be able to compete effectively in its market.

Future Outlook

The company expects expenses to increase as it pursues commercialization efforts, research and development activities, and operates as a public company. They estimate current funds will be sufficient to fund operations through the first half of 2028.

Management Comments

• The iLet was specifically designed to provide improvements in glycemic control relative to insulin pumps hybrid closed-loop systems, and MDI therapy without the complexity and management burden of current insulin pumps and hybrid closed-loop systems.
• The iLets core value proposition of marrying effective glycemic control with the simplicity of use that is brought about by adaptive closed-loop algorithm insulin dose determination may resonate particularly well among PCP who do not have the subspecialty-level of expertise, the resources, or the clinical bandwidth that is needed to initiate insulin-pump or hybrid closed-loop therapy or for the continual demand (such as adjustments at quarterly visits) those systems place on clinical practices in follow-on care.

Industry Context

The announcement highlights the increasing competition and innovation in the diabetes management space, with companies like Beta Bionics, Medtronic, Tandem, and Insulet vying for market share. The focus on automated insulin delivery systems and partnerships with CGM providers reflects a broader trend towards integrated and user-friendly diabetes solutions.

Comparison to Industry Standards

• Medtronic, Tandem Diabetes Care, and Insulet Corporation collectively hold approximately 96% market share in the insulin pump market.
• The iLet has certain characteristics that other insulin pumps manufactured by such competitors, as far as we are aware, do not currently have, such as the ability to be initialized with only the users body weight, being enabled by algorithms that determine 100% of the users insulin doses, no carb counting, an option for pay-as-you-go pharmacy reimbursement and prefilled cartridges.
• Insulet offers a product with a patch form factor, a feature not currently offered by Beta Bionics' iLet.

Related Party Transactions

• The company has entered into license agreements with Boston University, where a former co-founder was affiliated, and pays royalties based on net sales.
• The company has entered into a collaboration and license agreement with Xeris Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to revenue growth, but also risk of dilution from future capital raises.
• Employees: Job security and potential for career advancement due to company growth.
• Customers: Access to innovative diabetes management solutions with the iLet Bionic Pancreas.
• Suppliers: Increased demand for components and subassemblies used in the iLet.

Next Steps

• Continue commercialization efforts by educating PWD and HCPs on the potential benefits of the iLet.
• Build commercial and customer support infrastructure to maximize access to the iLet and customer retention.
• Leverage in-house manufacturing capabilities to optimize production efficiency and maintain quality.
• Obtain third-party coverage and reimbursement from payors under both DME and PBP channels.
• Increase addressable market by developing a patch pump and bihormonal iLet, as well as seeking expansion into the treatment of T2D.

Key Dates

Keywords

iLet Bionic Pancreas, insulin delivery, diabetes management, closed-loop algorithms, T1D, T2D, Beta Bionics, medical device